We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-... Kala Pharmaceuticals Inc is a biopharmaceutical company. The company is focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY Mucus Penetrating Particles, technology, with an initial focus on the treatment of eye diseases. AMPPLIFY particles are selectively-sized nanoparticles and have proprietary coatings. It has applied the AMPPLIFY technology to create nanosuspensions of loteprednol etabonate, or LE, acorticosteroid designed for ocular applications, resulting in two product candidates. INVELTYS was approved in August 2018 for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25 per cent is in Phase 3 development for the temporary relief of the signs and symptoms of dry eye disease. Show more
Ask ADVFN Intelligence (AI)
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for...
ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.38 | 5.66318926975 | 6.71 | 7.85 | 6.7 | 54418 | 7.4871282 | CS |
| 4 | 1.92 | 37.1373307544 | 5.17 | 7.85 | 4.95 | 33692 | 6.8934976 | CS |
| 12 | 0.93 | 15.0974025974 | 6.16 | 7.85 | 4.95 | 18463 | 6.43052134 | CS |
| 26 | 0.12 | 1.72166427547 | 6.97 | 7.88 | 4.21 | 121183 | 6.47319691 | CS |
| 52 | 1.59 | 28.9090909091 | 5.5 | 10.97 | 4.21 | 85747 | 6.91364175 | CS |
| 156 | -96.91 | -93.1826923077 | 104 | 114 | 3.5444 | 796800 | 34.40683751 | CS |
| 260 | -183.41 | -96.2782152231 | 190.5 | 734 | 3.5444 | 1081194 | 206.00912568 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
